2026年首个港股交易日，三大指数集体高开，恒指涨0.34%，国指涨0.4%，恒生科技指数涨0.58%。科 指成分股普遍高开，携程、网易涨超2%，理想汽车、京东健康、哔哩哔哩、蔚来、零跑汽车均涨超 1%。 ...

Market Performance - The Hong Kong Hang Seng Index opened with a gain of 0.34% and the Hang Seng Tech Index increased by 0.58% [1] - On its first day of trading, Wallen Technology surged by 82% [1] - Ctrip Group and NetEase both rose by over 2%, while Li Auto and JD Health saw increases of over 1% [1] Currency Movement - The offshore RMB against the US dollar broke above 6.97, reaching a new high since May 2023 [1]

京东健康(06618)发布公告，于2026年1月1日，公司根据首次公开发售后股份奖励计划向承授人授出了 涉及53.65万股新股份的53.65万股奖励股份，约占于授出日期已发行股份总数的0.02%。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表 任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何 責任。 JD Health International Inc. 京東健康股份有限公司 （於開曼群島註冊成立的有限公司） （股份代號：6618（港幣櫃台）及86618（人民幣櫃台）） 授出股份獎勵 董事會宣佈，於2026年1月1日，本公司根據首次公開發售後股份獎勵計劃向承授人授出 了涉及536,489股新股份的536,489股獎勵股份，約佔於授出日期已發行股份總數的0.02%。 授出的詳情如下： (iii) 86,560股獎勵股份將於授出日期起1至4年內歸屬。 授出74,078股獎勵股份的歸屬期間少於12個月，原因為該 等股份為出於行政管理原因在一年內分批授出的部分獎 勵。 1 授出日期： 2026年1月1日 承授人： 本集團僱員（不包括本集團董事及高級管理人員） 授出的對價： 零 授出獎勵股份的數目： 536,489股 授出日期股份的市價： 每股55.500港元 （附註） 歸屬期間： (i) 61,494股獎勵 ...

Core Viewpoint - The article emphasizes the significant advancements in the treatment of Amyotrophic Lateral Sclerosis (ALS) and the hope for future breakthroughs in medical science, particularly through collaboration among scientists, pharmaceutical companies, and patients [1][2][3]. Group 1: Treatment Advancements - The collaboration with Chinese scientists has led to the development of treatment drugs for SOD1 gene-type ALS, achieving world-leading clinical efficacy [1][2]. - Patients have reported dramatic improvements in their conditions, with some experiencing a 95% reduction in NFL (neurofilament light chain) levels, indicating significant recovery [1][8]. - The treatment has allowed patients to regain mobility and functionality, with some able to perform physical activities they could not do before [1][8]. Group 2: Research and Development - In 2025, the company facilitated nearly 100 ALS research projects in collaboration with over 60 top research teams and 50 biotech companies, resulting in breakthroughs in 15 drug pipelines and treatment technologies [11]. - The use of AI has accelerated research efforts, enabling the analysis of nearly 40,000 ALS research papers and hundreds of drug evaluations, significantly increasing research efficiency [11]. - The patient community has grown to over 18,000 registered individuals, providing a substantial database for real-world data research and clinical studies [11]. Group 3: Innovation in Care and Cost Reduction - A new care system for ALS patients has been established, focusing on comprehensive management to improve care quality and reduce costs [11][12]. - Collaborations with companies like Haier and JD Health have led to the development of customized, high-quality non-invasive ventilators at an 80% reduced cost for patients [11][12]. - The company has invested over 80 million yuan in research over the past 24 months, with a total investment exceeding 100 million yuan over six years, highlighting a commitment to advancing ALS treatment [11][12]. Group 4: Future Outlook - The year 2026 is anticipated to bring significant breakthroughs, with ongoing efforts to enhance AI-driven research and develop innovative care solutions [12]. - The company is exploring partnerships with robotics firms to create nursing robots that can assist with patient care, aiming to alleviate the burden on families [12]. - The overarching message is one of hope and determination, emphasizing that ALS can be conquered through collective efforts and scientific advancements [13].

Market Overview - The Hong Kong stock market experienced slight declines on the last trading day of 2025, with the Hang Seng Index closing at 25,630.54 points, down 0.87% [2] - Despite the daily drop, all three major indices maintained an upward trend for the second consecutive year, with the Hang Seng Index rising 27.77%, the Hang Seng Tech Index increasing by 23.45%, and the Hang Seng China Enterprises Index up by 22.27% for the year [2] Sector Performance - Major technology stocks mostly declined, with JD.com and Alibaba both falling over 1%, while internet healthcare stocks like JD Health and Ping An Good Doctor also dropped more than 1% [3] - Automotive stocks weakened, with Li Auto down nearly 3% and BYD down over 2% [3] - Conversely, airline stocks surged, with China Eastern Airlines rising nearly 5%, China Southern Airlines up over 4%, and Air China increasing by over 3% [3] New Listings - The newly listed company, Insilico Medicine, saw a significant increase of nearly 24% on its second day of trading, with its market capitalization surpassing 18 billion HKD [4] - Insilico Medicine, established in 2014, is a leading player in AI-driven drug discovery and development, having generated over 20 clinical or IND-stage assets through its Pharma.AI platform [7][8] - The company has licensed three assets to international pharmaceutical firms, with a total contract value of up to 2.1 billion USD [7] Entertainment Sector - The entertainment sector showed positive performance, with shares of Damai Entertainment rising nearly 6%, China Star Group up nearly 5%, and Maoyan Entertainment increasing by over 3% [9] - The total box office for the 2025 holiday season (November 28 to December 31) exceeded 5.245 billion CNY, marking the highest figure for the same period in nearly eight years, with a year-on-year increase of 76.35% [10]

Core Viewpoint - The Hong Kong stock market's Hang Seng Technology Index achieved a remarkable annual increase of 23.45% in 2025, marking its best performance since 2020, with 22 out of 30 constituent stocks rising [1] Group 1: Stock Performance - Among the 30 constituent stocks, notable performers included Hua Hong Semiconductor, which surged by 243.19%, Horizon Robotics with a rise of 140.56%, and SMIC increasing by 124.69% [1] - Other significant gainers were JD Health at 97.51%, Alibaba-W at 77.50%, Xpeng Motors-W at 70.10%, Baidu Group-SW at 59.01%, and Tencent Music-SW at 58.44% [1][2] Group 2: Investment Preferences - The first tier of investment preference is in semiconductor manufacturing (Hua Hong, SMIC) and core AI chips (Horizon Robotics), reflecting a strong focus on hard technology and domestic substitution logic [1] - The second tier includes growth sectors such as smart electric vehicles (Xpeng, Li Auto), AI applications (Baidu, SenseTime), and digital health (JD Health), which benefit from industry trends but still face competitive and profitability uncertainties [1] - The third tier consists of value recovery in platform internet giants (Alibaba, Tencent) and mature applications (NetEase, Kuaishou, Tencent Music), with gains primarily driven by profit realization and value reassessment through dividends and buybacks, categorized as "high-quality mature assets" [1]

Core Insights - The Hong Kong stock market closed 2025 with the Hang Seng Index rising by 27.77%, marking its best annual performance since 2017 [1] - Among the constituents of the Hang Seng Index, China Hongqiao surged by 203.72%, leading the gains, followed by Zijin Mining at 162.29%, and SMIC at 124.69% [1][2] Group 1: Performance Highlights - China Hongqiao's stock price reached 32.620 with a year-to-date increase of 203.72% [2] - Zijin Mining's stock price was 35.660, reflecting a year-to-date rise of 162.29% [2] - SMIC's stock price stood at 71.450, with a year-to-date increase of 124.69% [2] - Hansoh Pharmaceutical increased by 113.33% year-to-date, with a stock price of 36.080 [2] - Pop Mart's stock price was 37.700, showing a year-to-date rise of 111.46% [2] - Innovent Biologics saw a year-to-date increase of 108.33%, with a stock price of 76.250 [2] - Chow Tai Fook's stock price was 12.390, reflecting a year-to-date increase of 100.16% [2] - China Biologic Products had a stock price of 6.180, with a year-to-date rise of 98.71% [2] - JD Health's stock price was 55.500, showing a year-to-date increase of 97.51% [2] - China Life's stock price stood at 27.380, with a year-to-date increase of 96.60% [2] Group 2: Sector Analysis - The performance of the top stocks reflects four main themes: cyclical resources, hard technology, innovative pharmaceuticals, and niche consumption [1] - Stocks like China Hongqiao and Zijin Mining benefited from global inflation and industrial demand [1] - SMIC represents the core of domestic substitution and technological self-reliance [1] - Companies like Hansoh and Innovent are being valued for genuine innovation and international pricing [1] - Niche consumption sectors, represented by Pop Mart, Chow Tai Fook, and JD Health, demonstrate strong vitality even in a weak recovery environment [1]

Core Viewpoint - The Hong Kong Stock Connect Innovative Drug ETF (520880) has experienced a continuous decline for four days, reaching a new low since July 10, indicating a strong buying interest despite the downturn [1][2]. Group 1: Market Performance - The Hong Kong Stock Connect Innovative Drug ETF (520880) has seen a price drop of 0.80%, currently priced at 0.499, with a trading volume of 124,339 shares [1]. - The ETF has been in a downward trend since September, with the current adjustment lasting over three months, leading to the ETF trading below its issuance price [2]. Group 2: Investment Strategy - Analysts suggest that 2026 will be a strategic year for investing in innovative drugs, as the current market conditions may present a favorable entry point for investors [2]. - The ETF tracks the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, which has three key advantages: it exclusively includes innovative drug companies, has a high concentration of leading firms (over 72% in the top ten), and offers better risk control by reducing the weight of less liquid stocks [2][3]. Group 3: Composition and Risk Management - The top ten holdings of the ETF account for 72.57% of its total weight, showcasing a significant concentration in leading innovative drug companies [3]. - The ETF is designed to mitigate risks associated with less liquid stocks by enforcing a forced reduction in their weight, thus controlling tail risks effectively [2][3].

Group 1 - The Hong Kong innovation drug sector continues to experience a downturn, with leading companies like BeiGene and China Biologic falling over 1%, and Innovent Biologics and 3SBio dropping more than 3% [1][7] - The Hong Kong Innovation Drug ETF (520880) has seen a decline for four consecutive days, reaching a new low since July 10, with a premium rising inversely, indicating strong buying interest [8][1] - Recent analysis from Zhongyou Securities indicates that the innovation drug sector is in a continuous correction phase, primarily driven by a retreat from previously optimistic business development (BD) expectations [3][10] Group 2 - Looking ahead to 2026, the maturity of clinical data is expected to be a key factor driving the innovation drug market, with BD being a necessary outcome of enhanced competitiveness of domestic new drugs [3][10] - Dongwu Securities suggests that the current period may represent a favorable configuration window for the Hong Kong innovation drug sector, which has been in adjustment since September, lasting over three months [10] - The Hong Kong Innovation Drug ETF (520880) and its associated funds track the Hang Seng Hong Kong Innovation Drug Select Index, which has three unique advantages: it is purely focused on innovation drugs, has a high concentration of leading companies, and offers better risk control [10][11] Group 3 - The top ten holdings in the Hong Kong Innovation Drug ETF account for over 72% of the index, highlighting the dominance of leading companies in the sector [4][10] - The total market capitalization of the top ten companies in the ETF is approximately HKD 12.87 billion, with BeiGene having a weight of 11.51% and a market cap of HKD 3.07 billion [4][10] - For investors looking to reduce volatility while still focusing on innovation drugs, the only drug ETF in the market (562050) is recommended, which emphasizes both innovation drugs and traditional Chinese medicine [12][13]